Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
07 Novembre 2023 - 1:30PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
committed to advancing new standards of care for the frontline
treatment of hematologic malignancies, today announced that it will
host a live conference call and webcast at 8:30 a.m. ET on Tuesday,
November 14, 2023 to report its third quarter 2023 financial
results and provide a corporate update.
To access the live conference call, please dial (888) 259-6580
(domestic) or (416) 764-8624 (international) and refer to
conference ID 83649711. A webcast of the call will also be
available on the Investors & Media section of the Syros website
at www.syros.com. An archived replay of the webcast will be
available for approximately 30 days following the call.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the
frontline treatment of patients with hematologic malignancies.
Driven by the motivation to help patients with blood disorders that
have largely eluded other targeted approaches, Syros is developing
tamibarotene, an oral selective RARα agonist in frontline patients
with higher-risk myelodysplastic syndrome and acute myeloid
leukemia with RARA gene overexpression. For more information, visit
www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107787109/en/
Syros Karen Hunady Director of Corporate Communications
& Investor Relations 1-857-327-7321 khunady@syros.com
Investors Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024